Peter Ward

Peter Ward is an experienced pharmaceutical executive currently serving as Executive Director at Centessa Pharmaceuticals since June 2025. Previously, Peter held the position of Executive Director and Head of DMPK at Ultragenyx from March 2020 to May 2025, following a tenure as Scientific Director at Janssen from September 2014 to March 2020. Peter's career also includes significant roles at Johnson & Johnson as Principal Scientist in Preclinical Development and Senior Scientist, where responsibilities included planning and implementing ADME studies and regulatory interactions. Earlier experience as a Senior Research Biochemist at Merck involved leading biochemical toxicology assessments and managing safety studies, while at Arena Pharmaceuticals, Peter established an in vitro DMPK group. Educational credentials include a PhD in DMPK and Pharmacology from the University of North Carolina and a B.Sc in Biology from Queen's University.